These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. Vaduganathan M; McMurray JJV; Solomon SD Eur J Heart Fail; 2020 Sep; 22(9):1525-1530. PubMed ID: 32741093 [No Abstract] [Full Text] [Related]
4. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. Docherty KF; McMurray JJV Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240 [TBL] [Abstract][Full Text] [Related]
6. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
7. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD; Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? Konstam MA JACC Heart Fail; 2016 Oct; 4(10):823-825. PubMed ID: 27614938 [No Abstract] [Full Text] [Related]
11. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508 [No Abstract] [Full Text] [Related]
12. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940 [TBL] [Abstract][Full Text] [Related]
13. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Prenner SB; Shah SJ; Yancy CW Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]